A melanoma cell can dodge a targeted drug in dozens of different ways, each driven by a different genetic mutation. But what ...
Melanoma kills roughly 8,000 Americans each year, and a stubborn share of those deaths trace back to the same problem: tumors ...
Adding a second checkpoint inhibitor to chemotherapy improves outcomes among patients with non–small cell lung cancer (NSCLC) who have STK11 and/or KEAP1 mutations, according to the authors of a new ...
Despite the significance of immune checkpoint inhibitors (ICIs) in solid tumor treatment, identifying ICI-sensitive populations remains a challenge. Mutations in DNA damage response (DDR) pathway ...
In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...
The BRAF mutation affects a small percentage of non-small cell lung cancer (NSCLC) cases, making the cancer more difficult to treat. In recent years, advances in treatment have helped to improve ...
Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen ...